Glen Y Sato - Net Worth and Insider Trading

Glen Y Sato Net Worth

The estimated net worth of Glen Y Sato is at least $4,293 dollars as of 2024-11-10. Glen Y Sato is the SVP and CFO of PDL BioPharma Inc and owns about 1,738 shares of PDL BioPharma Inc (PDLI) stock worth over $4,293. Details can be seen in Glen Y Sato's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Glen Y Sato has not made any transactions after 2005-05-24 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Glen Y Sato

Glen Y Sato Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Glen Y Sato owns 3 companies in total, including Acucela Inc (AUCL) , PDL BioPharma Inc (PDLI) , and Exelixis Inc (EXEL) .

Click here to see the complete history of Glen Y Sato’s form 4 insider trades.

Insider Ownership Summary of Glen Y Sato

Ticker	Comapny	Transaction Date	Type of Owner
AUCL	Acucela Inc	2014-05-22	director
PDLI	PDL BioPharma Inc	2005-05-24	SVP and CFO
EXEL	Exelixis Inc	2003-05-15	CFO Sec and General Counsel

Glen Y Sato Latest Holdings Summary

Glen Y Sato currently owns a total of 1 stock. Glen Y Sato owns 1,738 shares of PDL BioPharma Inc (PDLI) as of May 24, 2005, with a value of $4,293.

Latest Holdings of Glen Y Sato

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
PDLI	PDL BioPharma Inc	2005-05-24	1,738	2.47	4,293

Holding Weightings of Glen Y Sato

Glen Y Sato Form 4 Trading Tracker

According to the SEC Form 4 filings, Glen Y Sato has made a total of 0 transactions in PDL BioPharma Inc (PDLI) over the past 5 years. The most-recent trade in PDL BioPharma Inc is the sale of 10,000 shares on May 24, 2005, which brought Glen Y Sato around $197,500.

Insider Trading History of Glen Y Sato

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Glen Y Sato Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Glen Y Sato Ownership Network

Ownership Network List of Glen Y Sato

No Data

Ownership Network Relation of Glen Y Sato

Glen Y Sato Owned Company Details

What does Acucela Inc do?

Who are the key executives at Acucela Inc?

Glen Y Sato is the director of Acucela Inc. Other key executives at Acucela Inc include EVP of Research & Development Lukas Scheibler , Chief Strategy Officer Roger Girard , and EVP of Legal Affairs George M Lasezkay .

Acucela Inc (AUCL) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Acucela Inc (AUCL) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Acucela Inc (AUCL) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Acucela Inc (AUCL)'s detailed insider trading history can be found in Insider Trading Tracker table.

Acucela Inc Insider Transactions

No Available Data

What does PDL BioPharma Inc do?

Who are the key executives at PDL BioPharma Inc?

Glen Y Sato is the SVP and CFO of PDL BioPharma Inc. Other key executives at PDL BioPharma Inc include President and CEO Dominique Monnet , VP & Gen. Counsel & Secretary Christopher Lewis Stone , and VP Finance & CAO and Acting CFO Edward Imbrogno .

PDL BioPharma Inc (PDLI) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of PDL BioPharma Inc (PDLI) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of PDL BioPharma Inc (PDLI) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

PDL BioPharma Inc (PDLI)'s detailed insider trading history can be found in Insider Trading Tracker table.

PDL BioPharma Inc Insider Transactions

No Available Data

What does Exelixis Inc do?

Who are the key executives at Exelixis Inc?

Glen Y Sato is the CFO Sec and General Counsel of Exelixis Inc. Other key executives at Exelixis Inc include CSO/EVP Disc & Trans Research Dana Aftab , EVP and General Counsel Jeffrey Hessekiel , and EVP and CFO Christopher J. Senner .

Exelixis Inc (EXEL) Insider Trades Summary

Over the past 18 months, Glen Y Sato made no insider transaction in Exelixis Inc (EXEL). Other recent insider transactions involving Exelixis Inc (EXEL) include a net sale of 330,710 shares made by Jeffrey Hessekiel , a net sale of 218,631 shares made by Dana Aftab , and a net purchase of 615,000 shares made by David Edward Johnson .

In summary, during the past 3 months, insiders sold 277,281 shares of Exelixis Inc (EXEL) in total and bought 0 shares, with a net sale of 277,281 shares. During the past 18 months, 1,231,265 shares of Exelixis Inc (EXEL) were sold and 735,409 shares were bought by its insiders, resulting in a net sale of 495,856 shares.

Exelixis Inc (EXEL)'s detailed insider trading history can be found in Insider Trading Tracker table.

Exelixis Inc Insider Transactions

No Available Data

Glen Y Sato Mailing Address

Above is the net worth, insider trading, and ownership report for Glen Y Sato. You might contact Glen Y Sato via mailing address: C/o Exelixis Inc, 170 Harbor Way, San Francisco Ca 94083.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.